BUFFALO, NY -- (Marketwire) -- 05/15/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) (the "Company") today announced that in conjunction with the termination of the NASDAQ OMX BX (formerly known as the Boston Stock Exchange) listing program, the Company will take steps to formally delist its common stock from that exchange. Specifically, the Company will file a Form 25 with the Securities and Exchange Commission in ten days effectuating this action. The Company's common stock ceased to be listed on the former Boston Stock Exchange in September 2007, and this action formalizes that cessation. This action has no effect on the Company's principal listing on the NASDAQ Capital Market.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2009.

Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com